中关村：多多药业西格列汀二甲双胍片获受理

Core Viewpoint - The announcement indicates that Duoduo Pharmaceutical, a subsidiary of Zhongguancun, has received an acceptance notice from the National Medical Products Administration for the marketing authorization application of Sitagliptin Metformin Tablets (II) [1] Group 1: Product Details - The drug is formulated to contain 50mg of Sitagliptin (as Sitagliptin phosphate) and 850mg of Metformin hydrochloride per tablet [1] - It is indicated for type 2 diabetes patients whose blood sugar is not adequately controlled by Metformin monotherapy or who are currently receiving a combination of both medications [1] Group 2: Financial Implications - As of the date of the announcement, the total research and development expenses for this project have reached 6.8755 million yuan [1] - If the drug is successfully approved, it is expected to enhance the market competitiveness of the company's antidiabetic products and positively impact the company's operating performance [1]